Pharma in China Being Held to Higher Standard, Says Greg Scott, ChinaBioSubmitted by Ayanna Monteverdi on Thu, 08/29/2013 - 11:49
Greg Scott, Founder, ChinaBioBio and Contact Info
Listen (5:03) Growth continuum in China unchanged
Listen (4:29) Why has China gone from 1st to 9th for outsourcing?
Listen (6:04) Perstective on GSK scandal
Listen (2:38) If you're not in China, you're missing out on soon to be second largest pharma market
Listen (3:57) Are you seeing innovation in China?
Listen (2:35) Living in China
Greg Scott is Mr. Bio in China. He's the CEO of ChinaBio, a sort of Burrill and Company located in Shanghai.
We caught up with Greg to see what's been happening in China this last year and to get his perspective on the recent GSK scandal. According to Greg, China is still the high growth story that it's been over the past few years. His message to others: If you're not in China you're missing out on what will soon be (next year?) the second largest pharma market in the world.
And what about the GSK scandal? Is it threatening pharma in China? Greg says the importance of the scandal cannot be underestimated. He argues that pharma's enterprises in China are being held to a higher standard, even than in the U.S. or Europe for various reasons. Greg is open about the issues and bullish on opportunity for bio in China.